08 Oct 2024
On October 8, 2024, Zhejiang Taimei Medical Technology Co., Ltd. (“Taimei Technology,” stock code: 02576.HK) officially announced its listing on the main board of the Hong Kong Stock Exchange.
At the listing ceremony, Mr. Zhao Lu, Chairman, Executive Director, and General Manager of Taimei Technology, along with Ms. Ni Xiaomei, Executive Director, Legal Director, and Board Secretary, struck the gong to mark the company’s new journey. Attendees included company executives, shareholder representatives, sponsors, and intermediaries involved in the IPO, all gathering to witness this significant milestone in Taimei Technology’s development.
Chairman, Executive Director, and CEO of Taimei Technology, Mr. Zhao Lu (left), along with Executive Director, General Counsel, and Board Secretary, Ms. Ni Xiaomei (right), rang the bell to mark the market opening.
At the listing ceremony, Mr. Zhao Lu, Chairman, Executive Director, and General Manager of Taimei Technology, along with Ms. Ni Xiaomei, Executive Director, Legal Director, and Board Secretary, struck the gong to mark the company’s new journey. Attendees included company executives, shareholder representatives, sponsors, and intermediaries involved in the IPO, all gathering to witness this significant milestone in Taimei Technology’s development.
In his speech, Mr. Zhao Lu stated, “Our successful entry into the Hong Kong capital market marks a new starting point for Taimei Technology. With the strength of the capital market behind us, we will remain committed to our mission of ‘harnessing digital power to make healthcare accessible.’ We will continue to innovate our products and services, improve operational quality and efficiency, and support the development and accessibility of effective medicines and medical devices, all while giving back to our investors for their trust and support.”
Mr. Zhao Lu, Chairman, Executive Director, and General Manager of Taimei Technology
Since its founding in 2013, Taimei Technology has focused on delivering advanced digital solutions for the pharmaceutical and medical device industries, benefiting patients worldwide. As of March 31, 2024, Taimei Technology provides over 40 software products and digital services across trial design and management, patient recruitment and follow-up, data collection, and analysis—addressing the diverse needs of various organizations and roles.
To address industry collaboration challenges, Taimei Technology developed two digital collaboration platforms: TrialOS and PharmaOS. These platforms effectively connect hospitals, pharmaceutical companies, third-party service providers, patients, and regulatory bodies, creating a unified standard for data flow, process integration, and resource sharing. This approach supports the digital transformation of the industry, enhancing R&D efficiency and post-market performance in pharmaceuticals and medical devices for shared value creation.
By March 31, 2024, Taimei Technology has served over 1,400 pharmaceutical companies and CROs, including 21 of the top 25 global pharmaceutical companies and 90 of China’s top 100 pharmaceutical innovators. The company has also partnered with over 700 certified drug trial institutions, with more than 80% being top-tier hospitals. Based on the number of clients, Taimei Technology is the most widely adopted digital solutions provider in China’s pharmaceutical R&D and marketing sectors.
